Halozyme Therapeutics HALO Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockValue.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding?
- Halozyme Therapeutics (HALO) reported preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding of $0 in Q1 2026.
- What does preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding mean?
- This represents the par value of preferred shares issued by the company, which carry specific rights and preferences over common stock, such as priority in dividend payments or liquidation. Preferred stock is a form of hybrid capital that sits between debt and common equity. If no shares are issued, this value remains at zero.